Investigative protocols assist you with the interpretation of some common laboratory result abnormalities and the investigation of some selected clinical conditions. They are derived from a set of protocols originally produced by Dr Noel Walmsley. Some of these have now been updated, and further protocols have been added over time by Dr John Roberts.

The range of investigative protocols cover conditions associated with:
Clinical Conditions
Abbreviation IP Title
Female Evaluation of ? androgen excess and/or hirsutism (female)
Female 1 Evaluation of female infertility
Female 2 Evaluation of irregular periods
Female 4 Hormonal changes during menstrual cycle
Prl High Causes of hyperprolactinaemia (prolactin >700 mIU/L)
Pot High Causes of hyperkalaemia: K+ >5.0
Coagulation Tests
Abbreviation IP Title
Platelet Platelet function analysis (2nd stage test)
Thrombosis Risk factors for venous thromboembolism
vWF1 von Willebrand disease
Drug Screen Interpretation
Abbreviation IP Title
Methadone Metabolite Evaluation of EDDP (methadone metabolite) results
THC Evaluation of 9-tetrahydrocannabinol (THC) results
UDS Urine drug screening
UDS Amph Evalution of sympathomimetic amine results
UDS Benzo Evaluation of benzodiazepine results
UDS Cocaine Evaluation of cocaine results
UDS Opiate Evaluation of opiate Results
Endocrine Tests
Abbreviation IP Title
TSH High Evaluation of an elevated serum TSH (>4.0mU/L)
TSH Low Evaluation of a subnormal serum TSH (<0.2 mU/L)
General Biochemistry
Abbreviation IP Title
Bicarb Low Causes of low plasma bicarbonate (HCO3 <18)
Calcium High 1 Causes of hypercalcaemia (calcium >2.6)
Calcium High 2 Evaluation of hypercalcaemia (calcium >2.6)
Calcium Low Evaluation of hypocalcaemia (calcium <2.2)
CK High Causes of an elevated CK (M >200 F >140)
Globulin High Evaluation of hyperglobulinaemia (globulins >44)
Glucose Low Evaluation of hyperglycaemia (plasma glucose <2.8mmol/L)
LDI Evaluation of lactate dehydrogenase isoenzymes (LDI)
MI Change Cardiac enzyme changes during myocardial infarction
Mag Low Causes of hypomagnesaemia (Mg <0.7mmol/L)
Phos High Causes of hyperphosphataemia (phosphate >1.8)
Phos Low Causes of hypophosphataemia (mild 0.5~0.65 mmol/L; severe <0.4mmol/L)
Polyuria Evaluation of polyuria (urine volume >3L/24hrs)
Pot High 1 Causes of hyperkalaemia (potassium >5.0)
Pot High 2 Evaluation of hyperkalaemia (potassium >5.0)
Pot Low 1 Causes of hypokalaemia (potassium <3.0)
Pot Low 2 Evaluation of hypokalaemia (potassium <3.0)
Sodium Low Causes of hyponatraemia (sodium <130)
Urate High Evaluation of hyperuricaemia (urate : M >0.45 F >0.40)
Immunology
Abbreviation IP Title
Plasma Cell Dys Evaluation of plasma cell dyscrasias
IgM Plasma Cell Dys Evaluation of IgM plasma cell dyscrasias
Coeliac Coeliac disease investigation
IgA Low Evaluation of selective IgA deficiency
DNA/ENA Anti-dsDNA and anti-ENA antibodies
Liver Function Tests
Abbreviation IP Title
ALP High 1 Causes of an isolated serum alkaline phosphatase (ALP) elevation (ALP >180IU/L)
ALP High 2 Serum alkaline phosphatase(ALP) elevation (ALP >180IU/L)
ALP High 3 Evaluation of an isolated serum alkaline phosphatase (ALP) elevation ?growth related (Age <19 y.o.)
ALP High 4 Serum alkaline phosphatase (ALP) elevation ?growth related (Age <19 y.o.)
ALP High 5 Marked Serum alkaline phosphatase (ALP) elevation (ALP >700IU/L Age <5 y.o.)
GGT High Causes of an elevated serum gamma glutamyl transferase (GGT) (GGT >100 U/L)
LD High Evaluation of an elevated serum lactate dehydrogenase (LD) (LD >300 U/L)
LFT 1 Evaluation of a moderate elevation of aminotransferase levels (AST & ALT)
LFT 2 Predominant hepatocellular pathology (ALT or AST >150U/L ALP <200 U/L)
LFT 3 Evaluation of a LFT pattern not typical of liver disease (elevated LD, AST>>ALT)
LFT 4 Causes of an isolated hyperbilirubinaemia (bili >25mmol/L, other LFT's normal)
LFT 5 Evaluation of an isolated hyperbilirubinaemia (bili >30mmol/L; other LFT"s normal)
LFT 6 Evaluation of jaundice (ALT <400U/L; ALP >350U/L)
LFT 7 Evaluation of jaundice (ALT >300U/L; ALP <350U/L)
LFT 8 Evaluation of localised cholestasis (ALP >180 U/L; ALT <150 U/L; GGT >100 U/L; Bilirubin <50 umol/L)
LFT 9 Evaluation of mixed hepatocellular and cholestatic disease (ALP >180 U/L; GGT >65 U/L; ALT or AST >150 U/L)
Microbiology & Patient Notes
Abbreviation IP Title
Haematuria Causes of isolated microscopic haematuria
Occult Blood Faecal occult blood
What is Barmah Forest Virus? Description of symptoms, treatment and prevention of Barmah Forest Virus.
What is Blastocystosis? Symptoms, infection period, diagnosis, treatment and prevention of Blastocystosis
What is Cryptosporidiosis? Symptoms, infection period, spread of infection and treatment of Cryptosporidiosis
What is Giardiasis? Symptoms, infection period, spread of infection, diagnosis, treatment and prevention of Giardiasis
What is Listeriosis? Symptoms, causes, infection period, diagnosis, treatment and prevention of Listeriosis
What is Parvovirus? Symptoms, causes, infection period, spread of infection, diagnosis, treatment and prevention of Parvovirus
What is Ross River Virus? Symptoms, infection period, spread of infection, diagnosis treatment and prevention of Ross River Virus
Serology
Abbreviation IP Title
Hep A Serological events in acute (self-limiting) Hepatitis A infection relative to Alanine Aminotransferase (ALT) peak
Hep B 1 Serological events in acute (self-limiting) Hepatitis B infection relative to Alanine Aminotransferese (ALT) peak
Hep B 2 Hepatitis B immune status
Pertussis Treatment of Bordetella Pertussis
Warfarin Management
Abbreviation IP Title
Warfarin 1 Range of International Normalised Ratio (INR) recommended for specific applications of Warfarin therapy.
Warfarin 2 Guidelines to the management of an elevated INR, with or without bleeding
Warfarin 3 Risk factors for bleeding complications of Warfarin therapy